Form 4: Apellis Pharmaceuticals Chief Scientific Officer Reports Stock Transactions

Apellis Pharmaceuticals' Chief Scientific Officer, Pascal Deschatelets, sold shares to cover tax obligations and received a restricted stock unit award.

Summary

• Pascal Deschatelets, the Chief Scientific Officer of Apellis Pharmaceuticals, sold 750 shares of common stock on January 17, 2025, at a price of $29.9582 per share.
• The sale was to cover tax withholding obligations related to restricted stock units.
• On January 21, 2025, Mr. Deschatelets was granted 15,045 restricted stock units.
• These restricted stock units vest 25% annually over four years from the grant date, contingent upon continued service.

Sentiment

Score: 6

Explanation: The document reflects routine stock transactions by an executive, which is neither particularly positive nor negative. The sale was for tax purposes and the grant is part of standard compensation.

Positives

• The grant of 15,045 restricted stock units to the Chief Scientific Officer indicates continued investment in the company's leadership.

Risks

• The sale of shares by an executive, even for tax purposes, could be perceived negatively by some investors.

Future Outlook

The restricted stock units will vest over the next four years, subject to continued service.

Industry Context

Stock transactions by company executives are a common occurrence and are often related to compensation and tax obligations. This filing is a routine disclosure of such activity.

Comparison to Industry Standards

• Stock-based compensation, including restricted stock units, is a standard practice in the biotechnology industry to incentivize and retain key personnel.
• The vesting schedule of 25% annually over four years is a typical vesting structure for such grants.
• Sales of shares to cover tax obligations are also common among executives who receive stock-based compensation.

Stakeholder Impact

• The stock sale may have a minor impact on the stock price, but it is unlikely to be significant.
• The grant of restricted stock units aligns the executive's interests with those of the shareholders.

Key Dates

Keywords

Apellis Pharmaceuticals, stock transaction, restricted stock units, insider trading, executive compensation, APLS, Pascal Deschatelets